Menu
Recent Uplist to OTCQB
Learn MorePatented Immunotherapy Candidate
Learn MoreBoard of Directors Expanded
Learn MoreDiscovery to Science-Led Public Company
Learn More
Previous slide
Next slide
Patented Immunotherapy Candidate
Learn MoreBoard of Directors Expanded
Learn MoreThe Journey from Discovery to IPO
Learn MoreCEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous slide
Next slide
Our patented approach, TLR-AD1 seeks to bolster the body’s immune system through cellular training; strengthening the body’s defense against cancer.
With TLR-AD1, we will provide Novel Access to the Global market.